is large (190 kilobases in the case of the Vysis probe), spanning the gene and then some (Fig. 1). “When you see changes in HER2 at the gene copy number level, is that a reflection of HER2 ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...